Results 101 to 110 of about 27,135 (258)

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Roscovitine derivative optimization via molecular dynamics reveals potent and selective CDK5 binders

Frontiers in Chemical Biology
CDK5 is an atypical member of the CDKs family that is not directly involved in cell cycle regulation but has a very relevant role in promoting DNA damage response and immune response evasion in cancer.
Lorenzo Botta, Giovanni Carotenuto, Manuel Arcieri, Elena Di Nisio, Valerio Perticaroli, Tiziana Castrignanò, Raffaele Saladino, Rodolfo Negri   +7 more
doaj   +1 more source

Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells.

PLoS Genetics, 2012
The cyclin-dependent kinases (CDKs) that promote cell-cycle progression are targets for negative regulation by signals from damaged or unreplicated DNA, but also play active roles in response to DNA lesions.
Lara Wohlbold, Karl A Merrick, Saurav De, Ramon Amat, Jun Hyun Kim, Stéphane Larochelle, Jasmina J Allen, Chao Zhang, Kevan M Shokat, John H J Petrini, Robert P Fisher   +10 more
doaj   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice

, 2014
International audienceResection of DNA double-strand breaks (DSBs) is a pivotal step during which the choice between NHEJ and HR DNA repair pathways is made.
Khanna, Kum Kum, Vanessa Camacho , Cristel, Burma, Sandeep, Ilcheva, Mariya, Tomimatsu, Nozomi, Hardebeck, Molly Catherine, Harris, Janelle Louise, Mukherjee, Bipasha, Porteus, Matthew, Llorente, Bertrand, Vanessa Camacho, Cristel   +10 more
core   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

Cancer Science, EarlyView.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah, Mackenzie M. Mayhew, Jacob Sellers, Russell G. Witt   +3 more
wiley   +1 more source

Controlling DNA-end resection: a new task for CDKs

Frontiers in Genetics, 2013
DNA double-strand breaks (DSBs) are repaired by two major pathways: homologous recombination (HR) and nonhomologous end-joining (NHEJ). The choice between HR and NHEJ is highly regulated during the cell cycle.
Lorenza P Ferretti, Lorenzo eLafranchi, Alessandro A Sartori   +2 more
doaj   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

Proteostasis of organelles in aging and disease

The FEBS Journal, EarlyView.
Cells rely on regulated proteostasis mechanisms to keep their internal compartments functioning properly. When these mechanisms fail, damaged proteins accumulate, disrupting organelles, such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosomes, as well as membraneless organelles, such as stress granules, processing bodies, the ...
Yara Nabawi, Cansu Doğan, Dunja Petrović, Gülce Perçin, Seda Koyuncu, David Vilchez   +5 more
wiley   +1 more source

Compromised DNA replication in gut cells underlies sensitivity to genotoxic stress in the tardigrade Hypsibius exemplaris

The FEBS Journal, EarlyView.
DNA damage in the tardigrade Hypsibius exemplaris elicits distinct cellular outcomes depending on replication status. While non‐replicating cells tolerate genotoxic stress, constitutively replicating cells undergo irreversible replication failure upon DNA damage, leading to loss of tissue homeostasis, fat depletion, sterility, and organismal death ...
Gonzalo Quiroga‐Artigas, Pauline Fontanié, Benjamin Lacroix, Maria Dolores Molina, María Moriel‐Carretero   +4 more
wiley   +1 more source